Novavax, Inc.
1.0 %
-54.39 %
Yet to be announced
Company Overview
Novavax, Inc. is a biotechnology company that develops and commercializes vaccines to prevent serious infectious diseases. The company's primary focus is on developing protein-based vaccines using its proprietary recombinant nanoparticle technology platform. Their main products include vaccines for COVID-19, seasonal influenza, and other infectious diseases.
Revenue Sources
PassNovavax generates its revenue primarily from the development and sale of vaccines, particularly its COVID-19 vaccine (NVX-CoV2373) and other vaccine candidates. The company's revenue streams come from product sales, grants, and collaboration agreements related to vaccine development and commercialization. None of these revenue sources are derived from haram activities.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Dec. 31, 2024 | $88.31m | $226.98m | - | $7.58m | 0.00% | 3.34% |
| Sept. 30, 2024 | $84.51m | $222.77m | - | $4.24m | 0.00% | 1.90% |
| June 30, 2024 | $415.48m | $258.63m | - | $4.14m | 0.00% | 1.60% |
| March 31, 2024 | $93.86m | $242.8m | - | $4.11m | 0.00% | 1.69% |
The company's interest expenses for the past four quarters have been consistently below 2% of total expenses. While the company does have some interest-bearing debt, the interest expense relative to total expenses remains minimal and within acceptable limits for halal investing.
Operational Ethics
PassBased on available information from SEC filings and company reports, Novavax does not maintain significant ongoing associations with entities involved in human rights violations. The company's primary operations and partnerships are focused in the United States and other countries without concerning ties to problematic regimes.
Comments